An expert panel of the EU drug regulator, the European Medicines Agency (EMA), endorsed seven new medicines for approval this ...

The U.S. is in "big danger" of falling behind in vaccine technology research as government funding declines and vaccine ...

Revenue -- $1.9 billion reported for the quarter, compared to prior sales cycles impacted by earlier U.S. COVID-19 vaccine ...

Investors watching the global biotech race may be sensing a shift after Moderna (NASDAQ:MRNA) co-founder and chairman Noubar ...

Moderna's narrative is shifting as analysts modestly trim their fair value from $37.32 to $35.78 per share and nudge the ...

Vinay Prasad, a top FDA official, blamed COVID shots for playing a role in the deaths of 10 children in a memo he sent to ...

Myocarditis is a known — but small — side effect of the mRNA Covid vaccines from Pfizer and Moderna, information that federal ...

A number of diseases tend to peak in the winter, thanks to indoor gatherings that help germs spread. The list includes not only colds and flu but also norovirus — a highly infectious cause of vomiting ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 6.4% in the afternoon session after a major long-term study from France indicated that its COVID-19 vaccine was safe and effective.

Dr. Vinay Prasad, the director of the FDA's vaccine division, did not provide data to back the claim in a memo sent to staff.

Shares of Moderna, Inc. (NASDAQ:MRNA) are trading lower Monday following reports suggesting tighter controls on how vaccines gain approval.